Smith, SG orcid.org/0000-0003-1983-4470, Foy, R orcid.org/0000-0003-0605-7713, McGowan, J et al. (5 more authors) (2017) General practitioner attitudes towards prescribing aspirin to carriers of Lynch Syndrome: findings from a national survey. Familial Cancer, 16 (4). pp. 509-516. ISSN 1389-9600
Abstract
A dose non-inferiority study comparing 100 mg, 300 mg and 600 mg of aspirin for cancer prevention among Lynch Syndrome carriers is underway (Colorectal Adenoma/Carcinoma Prevention Programme trial 3, CaPP3). To guide implementation of the findings, we investigated general practitioner (GP) attitudes towards aspirin prescribing for Lynch Syndrome carriers. We surveyed 1007 UK GPs (9.6% response rate). Using a within-subjects design, GPs read a statement on harms and benefits of aspirin and indicated their willingness to prescribe aspirin at three doses (100 mg, 300 mg, 600 mg). Approximately two-thirds (70.8%) of GPs had heard of Lynch Syndrome or its associated names, and among those 46.7% were aware of the cancer preventive effects of aspirin among carriers. Two-thirds (68.1%) of GPs reported feeling comfortable discussing harms and benefits of aspirin with a Lynch Syndrome patient. Willingness to prescribe was 91.3% at 100 mg, and declined to 81.8% at 300 mg and 62.3% at 600 mg (p < 0.001). In multivariable analyses, willingness to prescribe (600 mg) was higher among GPs ≥50 years (OR 1.46, 95% CI 1.03–2.07), more experienced GPs (OR 1.50, 95% CI 1.10–2.04), GPs who were aware of the cancer preventive effects of aspirin (OR 1.58, 95% CI 1.20–2.09), and those who reported seeing a Lynch Syndrome patient in practice (OR 1.44, 95% CI 1.01–2.05, p = 0.045). GPs report limited awareness of Lynch Syndrome and the preventive effects of aspirin among carriers. To ensure the optimal dose identified in the CaPP3 trial is readily available to patients, prescribing guidance and strategies to educate GPs should be developed.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
Keywords: | Aspirin; Implementation; Lynch Syndrome; Preventive therapy; Chemoprevention; Prescribing |
Dates: |
|
Institution: | The University of Leeds |
Academic Units: | The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Health Sciences (Leeds) > Academic Unit of Primary Care (Leeds) |
Depositing User: | Symplectic Publications |
Date Deposited: | 16 Mar 2017 15:59 |
Last Modified: | 23 Jun 2023 22:25 |
Status: | Published |
Publisher: | Springer Verlag |
Identification Number: | 10.1007/s10689-017-9986-9 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:113730 |